Search Our Site

NYCHH Triples Denials Recovery from UnitedHealthcare to $40.1M

NYCHH Triples Denials Recovery from UnitedHealthcare to $40.1M

NYC Health + Hospitals has more than tripled the amount sought in denied claims from UnitedHealthcare after a case-by-case review of high-profile denials. NYC Health + Hospitals (NYCHH) has more than tripled the amount the health system is seeking in claims recovery from UnitedHealthcare, from $11.1 million to $40.1 million after a comprehensive case-by-case review... Read More »

Read More →

NYC Health + Hospitals has more than tripled the amount sought in denied claims from UnitedHealthcare after a case-by-case review of high-profile denials. NYC Health + Hospitals (NYCHH) has more than tripled the amount the health system is seeking in claims recovery from UnitedHealthcare, from $11.1 million to $40.1 million after a comprehensive case-by-case review… Read More »

[...]

Read More

Report: Pfizer battles originators over biosimilars; but new study shows first one approved is equivalent

New York-based pharmaceutical company Pfizer is alleging that other large drugmakers are trying to block access to its biosimilar products and has taken the battle online, into the courts and to regulators, according to a news report. Bloomberg reported Tuesday that Pfizer has been battling companies like Johnson & Johnson, Amgen and Roche. Pfizer sought... Read More »

Read More →

New York-based pharmaceutical company Pfizer is alleging that other large drugmakers are trying to block access to its biosimilar products and has taken the battle online, into the courts and to regulators, according to a news report. Bloomberg reported Tuesday that Pfizer has been battling companies like Johnson & Johnson, Amgen and Roche. Pfizer sought… Read More »

[...]

Read More

Gilead to launch generic versions of hepatitis C drugs

Gilead Sciences said Monday it will launch generic versions of Harvoni and Epculsa, its top-selling hepatitis C drugs. Gilead will sell its chronic hepatitis C generics at a $24,000 list price for the most common course of therapy come January 2019. This represents a significant discount compared to the price for its branded alternatives, which... Read More »

Read More →

Gilead Sciences said Monday it will launch generic versions of Harvoni and Epculsa, its top-selling hepatitis C drugs. Gilead will sell its chronic hepatitis C generics at a $24,000 list price for the most common course of therapy come January 2019. This represents a significant discount compared to the price for its branded alternatives, which… Read More »

[...]

Read More

This Medical Clip May Be a Powerful Treatment for Heart Failure, Study Says

A seemingly simple but sophisticated clip may usher in a “new era” for patients suffering from a severe and difficult-to-treat complication of heart failure, according to a new study. The device, called the MitraClip, reduced hospitalizations related to heart failure by nearly half and deaths by nearly 40% among patients with a specific and serious... Read More »

Read More →

A seemingly simple but sophisticated clip may usher in a “new era” for patients suffering from a severe and difficult-to-treat complication of heart failure, according to a new study. The device, called the MitraClip, reduced hospitalizations related to heart failure by nearly half and deaths by nearly 40% among patients with a specific and serious… Read More »

[...]

Read More

Paralyzed people are beginning to walk with a new kind of therapy

Kelly Thomas woke up in a Florida hospital four years ago with no recollection of the car accident that had robbed her of the ability to walk. Thomas, an active college student who had barrel-raced in rodeos, moved to Kentucky for a year to try out a research study that she hoped would retrain her... Read More »

Read More →

Kelly Thomas woke up in a Florida hospital four years ago with no recollection of the car accident that had robbed her of the ability to walk. Thomas, an active college student who had barrel-raced in rodeos, moved to Kentucky for a year to try out a research study that she hoped would retrain her… Read More »

[...]

Read More

Hospitals Charge 479 Percent of Cost of Drugs on Average

THURSDAY, Sept. 20, 2018 — On average, hospitals mark up drugs by 479 percent of their cost, according to a report from The Moran Company, commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). Researchers from The Moran Company examined hospital markups for separately paid drugs using data from the Healthcare Provider Cost Reporting... Read More »

Read More →

THURSDAY, Sept. 20, 2018 — On average, hospitals mark up drugs by 479 percent of their cost, according to a report from The Moran Company, commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). Researchers from The Moran Company examined hospital markups for separately paid drugs using data from the Healthcare Provider Cost Reporting… Read More »

[...]

Read More

Senators Unveil Legislation To Protect Patients Against Surprise Medical Bills

% Quality Assurance With frustration growing among Americans who are being charged exorbitant prices for medical treatment, a bipartisan group of senators Tuesday unveiled a plan to protect patients from surprise bills and high charges from hospitals or doctors who are not in their insurance networks. The draft legislation, which sponsors said is designed to... Read More »

Read More →

% Quality Assurance With frustration growing among Americans who are being charged exorbitant prices for medical treatment, a bipartisan group of senators Tuesday unveiled a plan to protect patients from surprise bills and high charges from hospitals or doctors who are not in their insurance networks. The draft legislation, which sponsors said is designed to… Read More »

[...]

Read More

AbbVie is accused of paying kickbacks, using a stealthy network of nurses to promote Humira

Column Title In a wide-ranging scheme, AbbVie (ABBV) used a combination of old-fashioned kickbacks to doctors and a stealthy network of nurses to illegally boost prescriptions of its best-selling Humira treatment, according to a lawsuit filed on Tuesday by the California insurance commissioner. Over a five-year period, the drug maker offered physicians a familiar menu of... Read More »

Read More →

Column Title In a wide-ranging scheme, AbbVie (ABBV) used a combination of old-fashioned kickbacks to doctors and a stealthy network of nurses to illegally boost prescriptions of its best-selling Humira treatment, according to a lawsuit filed on Tuesday by the California insurance commissioner. Over a five-year period, the drug maker offered physicians a familiar menu of… Read More »

[...]

Read More

Hospitals Prepare To Launch Their Own Drug Company To Fight High Prices and Shortages

Sometimes IV bags are hard for hospitals to come by. Other times it’s injectable folic acid to treat anemias. Right now the tissue-numbing agent lidocaine is in short supply. Shortages of commonplace generic drugshave plagued hospitals in recent years. And with short supplies and fewer suppliers for key drugs, there have been price increases. Hospital... Read More »

Read More →

Sometimes IV bags are hard for hospitals to come by. Other times it’s injectable folic acid to treat anemias. Right now the tissue-numbing agent lidocaine is in short supply. Shortages of commonplace generic drugshave plagued hospitals in recent years. And with short supplies and fewer suppliers for key drugs, there have been price increases. Hospital… Read More »

[...]

Read More

Study finds multiple sclerosis drug slows brain shrinkage

  An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Robert J. Fox, M.D., Cleveland Clinic, OH. Results from a clinical trial of more than 250 participants with progressive multiple sclerosis(MS) revealed that ibudilast was better than a placebo in slowing down brain shrinkage. The study... Read More »

Read More →

  An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Robert J. Fox, M.D., Cleveland Clinic, OH. Results from a clinical trial of more than 250 participants with progressive multiple sclerosis(MS) revealed that ibudilast was better than a placebo in slowing down brain shrinkage. The study… Read More »

[...]

Read More

Page 3 of 49

Categories
Archives